|
COVID-19 and BRD4: a stormy and cardiotoxic bromo-romance
|
6
|
Resverlogix Corp.
|
Dec 14, 2021 11:50AM
|
|
Recent presentations
|
8
|
Resverlogix Corp.
|
Dec 13, 2021 11:00AM
|
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
1
|
Resverlogix Corp.
|
Dec 03, 2021 10:36AM
|
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
3
|
Resverlogix Corp.
|
Dec 02, 2021 10:46AM
|
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
1
|
Resverlogix Corp.
|
Dec 01, 2021 08:24PM
|
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
1
|
Resverlogix Corp.
|
Dec 01, 2021 02:54PM
|
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
5
|
Resverlogix Corp.
|
Nov 30, 2021 08:33AM
|
|
Re: Not good for the potential of apabetalone as a Covid-19 therapy
|
7
|
Resverlogix Corp.
|
Nov 29, 2021 05:30PM
|
|
Not good for the potential of apabetalone as a Covid-19 therapy
|
9
|
Resverlogix Corp.
|
Nov 29, 2021 02:29PM
|
|
Resverlogix Receives Ethics Approval for Canadian Sites in Apabetalone COVID-19 Clinical Trial
|
3
|
Resverlogix Corp.
|
Oct 12, 2021 06:37PM
|
|
Zenith Epigenetics and Newsoara Announce Initiation of Phase 2b mCRPC Study Evaluating Combination of ZEN-3694 and Enzalutamide
|
6
|
Zenith Epigenetics
|
Sep 21, 2021 10:43AM
|
|
Re: Study Demonstrates Resverlogix’s Apabetalone Significantly Improves Cognition & Reduces Cognitive Decline Among Patients with Both CVD & Diabetes
|
7
|
Resverlogix Corp.
|
Sep 13, 2021 10:00AM
|
|
Study Demonstrates Resverlogix’s Apabetalone Significantly Improves Cognition & Reduces Cognitive Decline Among Patients with Both CVD & Diabetes
|
7
|
Resverlogix Corp.
|
Sep 13, 2021 09:57AM
|
|
Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
|
8
|
Resverlogix Corp.
|
Sep 08, 2021 08:22AM
|
|
BETonMACE Cognition Sub-Study Published
|
14
|
Resverlogix Corp.
|
Sep 01, 2021 10:43AM
|
|
Zenith Epigenetics Announces Publication in Journal of Cancer Gene Therapy with Compelling Data for Treatment of ER-Positive Breast Cancer Patients
|
3
|
Zenith Epigenetics
|
Aug 17, 2021 09:42PM
|
|
Bioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB3TM Fusion Protein Comprising Iduronate-2-sulfatas...
|
3
|
BIOASIS TECHNOLOGIES INC
|
Aug 10, 2021 12:37PM
|
|
New Zenith Drug ZEN-3365 Publication
|
3
|
Zenith Epigenetics
|
Aug 04, 2021 12:08PM
|
|
Re: New video
|
4
|
Resverlogix Corp.
|
Aug 03, 2021 10:28AM
|
|
ESC 2021 August 27-30
|
12
|
Resverlogix Corp.
|
Aug 02, 2021 05:41PM
|
